Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
TIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.62 - $92.00
Previous CloseN/A
Volume80.17K
Average Volume (3M)99.25K
Market Cap
$163.15M
Enterprise Value$403.02M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta6.69
Next Earnings
Mar 10, 2025EPS Estimate
-3.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.55
Shares Outstanding6,525,887
10 Day Avg. Volume95,721
30 Day Avg. Volume99,245
Standard Deviation0.61
R-Squared0.02
Alpha-0.00416
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)112.42
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-84.74
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$114.00Price Target Upside374.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Instil Bio News
PremiumCompany Announcements
Instil Bio Secures Loan to Refinance Facility
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe SYN-2510 1L NSCLC chemo combo trial has begun dosing with plans to escalate and enroll around 60 patients by the end of the year, indicating progress in clinical trials.
Market PotentialIncreased investor interest in the PD-1xVEGF space is seen as supportive of building enthusiasm for the mechanism, with Instil shares expected to rise as enthusiasm grows.
Potential AcquisitionInstil Bio is seen as a potential target for acquisition as more players enter the PD-1/L1 x VEGF market.
Bears Say
Financial PerformanceA net loss for 3Q24 of $3.54 per share was reported versus an estimated net loss of $3.08 per share.
Stock ValuationThe stock is characterized as speculative risk, indicating a higher level of uncertainty and potential volatility.
Trial DelaysThe timeline delay for the U.S. trial is due to CRO contract negotiations and hiring of clinical development employees.
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $9.62 and its highest was $92.00 in the past 12 months.
What is Instil Bio’s market cap?
Instil Bio’s market cap is $163.15M.
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is Mar 10, 2025 which is in 16 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on Nov 13, 2024. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.108 by -$1.432.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate is -3.22.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,525,887 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.108. Following the earnings report the stock price went down -5.512%.
Which hedge fund is a major shareholder of Instil Bio?
Currently, no hedge funds are holding shares in TIL
---
Instil Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.00 (374.80% Upside)
$114.00 (374.80% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
118.70%
12-Months-Change
Fundamentals
Return on Equity
-36.63%
Trailing 12-Months
Asset Growth
-19.90%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
---
TIL Stock 12 Month Forecast
Average Price Target
$114.00
▲(374.80% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TIL
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-26.05%
reiterated a buy rating 3 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -26.05% per trade.
---